VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery s ...

A new study reveals that biochar can create tiny but powerful soil microenvironments that significantly reduce cadmium contamination in crops. The ...

The study evaluates how omega-3 delivery architecture influences triglyceride outcomes and omega-3 incorporation in ...

Bionxt Solutions has reported significant progress in its primary development program, with new preclinical data paving the way for initial human trials. The company is also broadening its strategic ...

At the heart of Bionxt's clinical strategy is a novel sublingual, orally dissolving film (ODF) formulation of the drug Cladribin. Cladribin is already an approved tablet therapy for Multiple Sclerosis ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Marine biotechnology and material science convergence is fundamentally transforming packaging capabilities. The integration ...

Niclosamide is an old antiparasitic with documented anticancer activity in laboratory models, but its clinical use for cancer has been limited by poor solubility and bioavailability. The authors ...

Stability is a critical factor in drug formulation, with implications for product quality, lifecycle management, and ...

In this interview, Dr. Steve Ward-Smith explores the analytical challenges and opportunities shaping the development of nasal spray therapeutics.

Cymbiotika’s move into Target and fresh $25 million raise mark a new chapter for the science-first wellness brand.